Dapagliflozin in phenotypically stratified HFpEF without myocardial fibrosis: the STADIA-HFpEF randomized crossover trial.
A diabetes drug didn't improve heart function in patients with preserved ejection fraction and minimal scarring, guiding more targeted treatment choices.
This randomized crossover trial tested dapagliflozin in patients with heart failure with preserved ejection fraction and no significant myocardial fibrosis. Dapagliflozin did not improve left-ventricular distensibility or relaxation, although left-atrial conduit strain and inflammatory biomarkers showed limited favorable signals.
What the study was
- Study design
- Randomized crossover trial
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- European heart journal. Cardiovascular pharmacotherapy
Why it surfaced
High triage score (9/10) based on study design (Randomized crossover trial) and direct clinical relevance; matched topic: Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk; flag: 🟠 Novel or significantly improved treatment
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.